個人簡介：
潘雪華博士2015年于香港理工大學(xué)獲得分子生物學(xué)博士學(xué)位，2018年至2024年主要在企業(yè)從事蛋白和核酸藥物臨床前研究，2024年加入南方科技大學(xué)翟繼先教授課題組，研究植物polyA相關(guān)蛋白的分子機(jī)制以及核酸藥物的開發(fā)。
研究領(lǐng)域：
植物polyA相關(guān)蛋白的分子機(jī)制；
核酸藥物研究。
學(xué)術(shù)成果：
論文
1. Feng S, Rcheulishvili N, Jiang X, Zhu P, Pan X, Wei M, Wang PG, Ji Y, Papukashvili D. A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach. Int J Biol Sci. 2024 Mar 17;20(6):2111-2129
2. Qiu X, Li N, Yang Q, Wu S, Li X, Pan X, Yamamoto S, Zhang X, Zeng J, Liao J, He C, Wang R, Zhao Y. The potent BECN2-ATG14 coiled-coil interaction is selectively critical for endolysosomal degradation of GPRASP1/GASP1-associated GPCRs. Autophagy. 2023 Nov;19(11):2884-2898
3. Wang X, Liu C, Rcheulishvili N, Papukashvili D, Xie F, Zhao J, Hu X, Yu K, Yang N, Pan X, Liu X, Wang PG, He Y. Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa. NPJ Vaccines. 2023 May 25;8(1):76
4. Gaurav AK, Afrin M, Yang X, Saha A, Sayeed SKA, Pan X, Ji Z, Wong KB, Zhang M, Zhao Y, Li B. The RRM-mediated RNA binding activity in T. brucei RAP1 is essential for VSG monoallelic expression. Nat Commun. 2023 Mar 22;14(1):1576.
5. Shen Z, Liu C, Wang Z, Xie F, Liu X, Dong L, Pan X, Zeng C, Wang PG. Development of a Library of Disulfide Bond-Containing Cationic Lipids for mRNA Delivery. Pharmaceutics. 2023 Feb 1;15(2):477.
6. Rcheulishvili N, Mao J, Papukashvili D, Liu C, Wang Z, Zhao J, Xie F, Pan X, Ji Y, He Y, Wang PG. Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness. Int J Biol Macromol. 2023 Jan 31;226:885-899.
7. Afrin M, Gaurav AK, Yang X, Pan X, Zhao Y, Li B. “TbRAP1 has an unusual duplex DNA binding activity required for its telomere localization and VSG silencing”. Science Advances. (2020) 18; 6(38).
8. He, Y, Lei, J, Pan, X. et al. “The hydrolytic water molecule of Class A β-lactamase relies on the acyl-enzyme intermediate ES* for proper coordination and catalysis”. Scientific reports (2020), 10: 10205
9. Pan X, He Y, Chan K, et al. “Modified penicillin with carbapenem-like stereochemistry as specific inhibitor of Class C β-lactamases”. Antimicrobial Agents and Chemotherapy, 2017: AAC. 01288-17.
10. Pan X, He Y, Lei J, et al. “Crystallographic snapshots of Class A β-lactamase catalysis reveal structural changes that facilitate β-lactam hydrolysis”. Journal of Biological Chemistry (2017), 292(10): 4022-4033.
11. Pan X, Wong WT, He Y, Jiang Y and Zhao Y. “Perturbing the general base residue Glu166 in the active site of Class A β-lactamase leads to enhanced carbapenem binding and acylation”. Biochemistry (2014),53:5414-5423.
12. Guo J, Pan X, Zhao Y, Chen S. “Engineering Clostridia Neurotoxins with elevated catalytic activity”. Toxicon (2013),74:158-66
專利
1. 糖類膽固醇結(jié)構(gòu)、脂質(zhì)體納米顆粒、組合物及其應(yīng)用， 專利申請?zhí)枺?024105353785，王鵬,曾臣,朱國鋒,劉興武,杜琳琳,劉曉藝,潘雪華
2. 一種糖類脂質(zhì)分子、藥物遞送載體、藥物復(fù)合物及其用途，專利申請?zhí)枺?024105366874， 王鵬,程漢超,梁志芬,朱國鋒,金佳慧,潘雪華
3. 一種用于mRNA合成的氘代加帽化合物及其制備方法和應(yīng)用，專利申請?zhí)枺篊N117820388A，曹學(xué)峰 于宏超 潘雪華 丁碩，陳天毓。
4. 用于檢測丁酰膽堿酯酶的熒光探針及其應(yīng)用, 專利申請?zhí)枺?nbsp;201810247083.2，潘雪華。
5. C類β-內(nèi)酰胺酶抑制劑及其制備方法和應(yīng)用，專利號：ZL 2017 1 0790073.9，潘雪華，賀云嬌，陳建輝，趙燕湘。
6. 一種3，5二取代吡唑的合成方法，專利號：200710094137 李建源，潘雪華，季麗，賀海鷹。
